Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amgen (AMGN)

Amgen terminates Kyowa Kirin license and collaboration agreement from June 2021

Neutral Impact 3 of 5 product/contract Written later

Amgen and Kyowa Kirin signed a Termination Agreement on January 30, 2026, to end their License and Collaboration Agreement dated June 1, 2021. The termination takes effect only after regulatory approval is received, and the filing gives no financial terms or reasons.

Key points

  • Termination Agreement dated January 30, 2026 with Kyowa Kirin Co., Ltd.
  • Ends the License and Collaboration Agreement dated June 1, 2021
  • Termination is effective upon receipt of regulatory approval
  • Agreement filed as Exhibit 10.1; portions omitted as not material

The filing

CompanyAmgen (AMGN)
Form8-K, current report
Filed with the SECJan 30, 2026, 8:00 AM ET
Accession number0001193125-26-030518

Items reported: 1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.